Category: Cannabis Info-2

Why cannabis holds real promise as a treatment for cancer, according to a sweeping new study

Why cannabis holds real promise as a treatment for cancer, according to a sweeping new study

May 7, 2025 (updated October 8, 2025) Published by



A new study suggests that researchers should take a closer look at cannabis as a treatment for cancer and its symptoms. The team behind the study says the results suggest the federal government should remove restrictions on that research.

An organization called Cancer Playbook, which is based in Evergreen, paid for the study. Cancer Playbook’s head of research says it works to provide people battling cancer with information about what treatments have helped other cancer patients – and that often includes medical marijuana.

The study reviewed more than 10,000 published papers on medical cannabis. That makes it the most comprehensive analysis ever conducted on the topic, according to a recent story in The Guardian.

Ryan Castle is the director of research for Cancer Playbook and he led the study. It found that cannabis showed clear promise in many aspects of cancer treatment, from reducing pain to shrinking tumors.

Ryan talked with Erin O’Toole about study and why it’s hard to get reliable data on the effectiveness of medical marijuana – which is legal in Colorado and many other states, but still illegal at the federal level.





Source link

Nebraska patients inch closer to medical cannabis

Nebraska patients inch closer to medical cannabis

May 7, 2025 (updated October 8, 2025) Published by







Source link

Director of a colony from Mykolaiv region caught with cannabis in his pocket :: Intent :: Ukrainian Media:: Intent

Director of a colony from Mykolaiv region caught with cannabis in his pocket :: Intent :: Ukrainian Media:: Intent

May 7, 2025 (updated October 8, 2025) Published by


In Mykolaiv region, a colony director was tried for using cannabis. He hid it and carried it with him to work. The court fined the official, and the drugs were seized.

This is evidenced by the ruling of the Voznesensk City District Court of Mykolaiv Oblast.

The director of a branch of Voznesenskaya penal colony No. 72 was fined for illegal drug possession. As the court found, one autumn morning last year, the accused found wild cannabis plants growing on the bank of the Mertvovod River near the food and flavor factory in Voznesensk. He cut off the leaves and inflorescences, took them to his house, where he dried and crushed the drug.

Already on April 17, 2025, the director of the colony came to work with a power bank, inside of which, in the inner pocket of his jacket, was a package of cannabis. Due to his official authority, he had unimpeded access to the territory of the institution. However, during the inspection in the care room, the staff of the institution checked the power bank and found a polymer package with a narcotic substance of plant origin.

The police seized the substance. The court found the official guilty of committing a criminal offense under Part 1 of Art. 309 of the Criminal Code of Ukraine – illegal manufacture, purchase and storage of drugs without the purpose of sale. In sentencing, the court took into account the defendant’s sincere repentance, positive character, lack of criminal record, complete higher education, and the fact that he is not registered with a narcologist or psychiatrist.

The court fined him UAH 17,000 and ordered him to pay UAH 1,782 in forensic costs. The power bank itself will be returned to the owner, and the drug substance will be destroyed. The verdict can be appealed within 30 days.

Also, in the Mykolaiv pre-trial detention center, an internal service sergeant was caught by law enforcement officers when he tried to smuggle drugs and psychotropic substances for one of the prisoners for a reward. It all started in 2024, when the inspector met the prisoner while on duty, and he offered to smuggle drugs for money – and he agreed.


Анна Бальчінос



Source link

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction USA – English Israel – English

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction USA – English Israel – English

May 7, 2025 (updated October 8, 2025) Published by


TORONTO and GLIL YAM, Israel, May 7, 2025 /PRNewswire/ — IM Cannabis Corp. (Nasdaq: IMCC) (CSE: IMCC) (the “Company” or “IM Cannabis“), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the “April 11 Release“), it has filed a management information circular (the “Circular“) in connection with the upcoming annual general and special meeting of the shareholders of the Company (“Shareholders“) to be held on May 23, 2025 (the “Meeting“). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.

Meeting Details

The Company’s board of directors (the “Board“) has set March 31, 2025 as the record date (the “Record Date“) for determining the Shareholders entitled to receive notice of and vote at the Meeting. The Meeting will be held at the offices of Company’s legal counsel, Garfinkle Biderman LLP, located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9 on Friday, May 23, 2025 at 10:00 a.m. (Toronto time).

To be effective, proxies in respect of the Meeting must be duly completed, signed and returned in the envelope provided for that purpose to Computershare Trust Company of Canada, 8th Floor, 100 University Ave, Toronto, Ontario M5J 2Y1, by courier, by mail, by phone at 1-866-732-8683 (Toll Free North America) / 312-588-4290 (International Direct Dial) or by electronic voting through www.investorvote.com in each case by 10:00 a.m. (Toronto time) on May 21, 2025, or in the event of an adjournment or postponement of the Meeting, 48 hours before the time of the adjourned or postponed Meeting (excluding Saturdays, Sundays and holidays). Votes cast electronically are in all respects equivalent to, and will be treated in the exact same manner as, votes cast via a paper instrument of proxy. Further details on the electronic voting process are provided in the instrument of proxy.

The Company has elected to use the “notice-and-access” mechanism provided for under National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer to deliver the Meeting materials to non-registered Shareholders, including the Circular, notice of Meeting, consolidated audited financial statements of the Company for the financial years ended December 31, 2024, and 2023 and the auditors’ report thereon and accompanying management’s discussion and analysis. This means that, rather than receiving paper copies of the Meeting materials in the mail, non-registered Shareholders as of the Record Date will have access to electronic copies of the Meeting materials at https://investors.imcannabis.com and under the Company’s SEDAR+ and EDGAR profiles at www.sedarplus.ca and www.sec.gov/edgar. The Meeting materials will remain on the Company’s website for a period of one year. Notice-and-access will not be used for the registered Shareholders and registered Shareholders will instead receive a paper copy of the Meeting materials and all proxy related materials in the mail.

For a description of the matters being considered at the Meeting, please refer to the Circular and Meeting materials.

Additional Information on the Focus Transaction

The Company wishes to provide Shareholders with additional information on the proposed Focus Transaction. To determine the Focus Purchase Price, the Board commissioned an arm’s length independent third-party, Beta Finance T.Y.S Ltd., a leading financial consulting company in Israel. Utilizing a discounted cash flow income approach, they determined the value of Focus, as of December 31, 2024, to be approximately NIS 3.1 million based on the future cash flow expected to be generated by its operations. Applying this analysis, it was determined that a 26% interest in Focus would be worth approximately NIS 818,740.

The Company, IMC Holdings and Ewave agreed that to preserve the Company’s cash, they intend to settle the Focus Purchase Price through the issuance of Common Shares, calculated on the basis of a deemed price per Common Share equal to the greater of: (x) the ten-day volume weighted average price of the Common Shares on the CSE ending on the date the Company receives disinterested shareholders’ approval to complete the Focus Transaction; and (y) the discounted market price pursuant to the policies of the CSE.

The Board (excluding the conflicted director) unanimously determined the Focus Transaction to be in the best interests of the Company and recommends the approval of the Focus Transaction and Focus Transaction Resolution (as such term is defined in the Circular) by disinterested Shareholders at the Meeting.

Your vote is important. Whether or not you plan to attend the Meeting, we encourage you to vote promptly.

About IM Cannabis Corp.

IM Cannabis (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the Company holding the Meeting on the date and time set out herein; the Company’s plan to seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company’s plan to complete the Focus Transaction.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company will hold the Meeting on the date and time set out herein; the Company will seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company completing the Focus Transaction.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s inability to continue to meet the listing requirements of the CSE and the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company’s inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company’s inability to realize upon its retail presence, distribution capabilities and data-driven insights; the Company not holding the Meeting on the date and time as set out herein; the Company not receiving disinterested Shareholder approval to complete the Focus Transaction at the Meeting; the Company not completing the Focus Transaction; and the risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report on Form 20-F dated March 31, 2025, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko,
Director Investor & Public Relations IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
[email protected]

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

SOURCE IM Cannabis Corp.



Source link

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 (updated October 8, 2025) Published by


TORONTO and GLIL YAM, Israel, May 7, 2025 /PRNewswire/ — IM Cannabis Corp. (Nasdaq: IMCC) (CSE: IMCC) (the “Company” or “IM Cannabis“), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the “April 11 Release“), it has filed a management information circular (the “Circular“) in connection with the upcoming annual general and special meeting of the shareholders of the Company (“Shareholders“) to be held on May 23, 2025 (the “Meeting“). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.

 

IM Cannabis Logo
IM Cannabis Logo

 

Meeting Details

The Company’s board of directors (the “Board“) has set March 31, 2025 as the record date (the “Record Date“) for determining the Shareholders entitled to receive notice of and vote at the Meeting. The Meeting will be held at the offices of Company’s legal counsel, Garfinkle Biderman LLP, located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9 on Friday, May 23, 2025 at 10:00 a.m. (Toronto time).

To be effective, proxies in respect of the Meeting must be duly completed, signed and returned in the envelope provided for that purpose to Computershare Trust Company of Canada, 8th Floor, 100 University Ave, Toronto, Ontario M5J 2Y1, by courier, by mail, by phone at 1-866-732-8683 (Toll Free North America) / 312-588-4290 (International Direct Dial) or by electronic voting through www.investorvote.com in each case by 10:00 a.m. (Toronto time) on May 21, 2025, or in the event of an adjournment or postponement of the Meeting, 48 hours before the time of the adjourned or postponed Meeting (excluding Saturdays, Sundays and holidays). Votes cast electronically are in all respects equivalent to, and will be treated in the exact same manner as, votes cast via a paper instrument of proxy. Further details on the electronic voting process are provided in the instrument of proxy.

The Company has elected to use the “notice-and-access” mechanism provided for under National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer to deliver the Meeting materials to non-registered Shareholders, including the Circular, notice of Meeting, consolidated audited financial statements of the Company for the financial years ended December 31, 2024, and 2023 and the auditors’ report thereon and accompanying management’s discussion and analysis. This means that, rather than receiving paper copies of the Meeting materials in the mail, non-registered Shareholders as of the Record Date will have access to electronic copies of the Meeting materials at https://investors.imcannabis.com and under the Company’s SEDAR+ and EDGAR profiles at www.sedarplus.ca and www.sec.gov/edgar. The Meeting materials will remain on the Company’s website for a period of one year. Notice-and-access will not be used for the registered Shareholders and registered Shareholders will instead receive a paper copy of the Meeting materials and all proxy related materials in the mail.

For a description of the matters being considered at the Meeting, please refer to the Circular and Meeting materials.

Additional Information on the Focus Transaction

The Company wishes to provide Shareholders with additional information on the proposed Focus Transaction. To determine the Focus Purchase Price, the Board commissioned an arm’s length independent third-party, Beta Finance T.Y.S Ltd., a leading financial consulting company in Israel. Utilizing a discounted cash flow income approach, they determined the value of Focus, as of December 31, 2024, to be approximately NIS 3.1 million based on the future cash flow expected to be generated by its operations. Applying this analysis, it was determined that a 26% interest in Focus would be worth approximately NIS 818,740.

The Company, IMC Holdings and Ewave agreed that to preserve the Company’s cash, they intend to settle the Focus Purchase Price through the issuance of Common Shares, calculated on the basis of a deemed price per Common Share equal to the greater of: (x) the ten-day volume weighted average price of the Common Shares on the CSE ending on the date the Company receives disinterested shareholders’ approval to complete the Focus Transaction; and (y) the discounted market price pursuant to the policies of the CSE.

The Board (excluding the conflicted director) unanimously determined the Focus Transaction to be in the best interests of the Company and recommends the approval of the Focus Transaction and Focus Transaction Resolution (as such term is defined in the Circular) by disinterested Shareholders at the Meeting.

Your vote is important. Whether or not you plan to attend the Meeting, we encourage you to vote promptly.

About IM Cannabis Corp.

IM Cannabis (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the Company holding the Meeting on the date and time set out herein; the Company’s plan to seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company’s plan to complete the Focus Transaction.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company will hold the Meeting on the date and time set out herein; the Company will seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company completing the Focus Transaction.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s inability to continue to meet the listing requirements of the CSE and the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company’s inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company’s inability to realize upon its retail presence, distribution capabilities and data-driven insights; the Company not holding the Meeting on the date and time as set out herein; the Company not receiving disinterested Shareholder approval to complete the Focus Transaction at the Meeting; the Company not completing the Focus Transaction; and the risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report on Form 20-F dated March 31, 2025, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko,
Director Investor & Public Relations IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/im-cannabis-announces-filing-of-information-circular-for-upcoming-annual-general-and-special-meeting-and-provides-additional-information-on-the-focus-transaction-302448387.html

SOURCE IM Cannabis Corp.



Source link

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 (updated October 8, 2025) Published by


TORONTO and GLIL YAM, Israel, May 7, 2025 /CNW/ — IM Cannabis Corp. (Nasdaq: IMCC) (CSE: IMCC) (the “Company” or “IM Cannabis“), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the “April 11 Release“), it has filed a management information circular (the “Circular“) in connection with the upcoming annual general and special meeting of the shareholders of the Company (“Shareholders“) to be held on May 23, 2025 (the “Meeting“). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.

 

IM Cannabis Logo
IM Cannabis Logo

 

Meeting Details

The Company’s board of directors (the “Board“) has set March 31, 2025 as the record date (the “Record Date“) for determining the Shareholders entitled to receive notice of and vote at the Meeting. The Meeting will be held at the offices of Company’s legal counsel, Garfinkle Biderman LLP, located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9 on Friday, May 23, 2025 at 10:00 a.m. (Toronto time).

To be effective, proxies in respect of the Meeting must be duly completed, signed and returned in the envelope provided for that purpose to Computershare Trust Company of Canada, 8th Floor, 100 University Ave, Toronto, Ontario M5J 2Y1, by courier, by mail, by phone at 1-866-732-8683 (Toll Free North America) / 312-588-4290 (International Direct Dial) or by electronic voting through www.investorvote.com in each case by 10:00 a.m. (Toronto time) on May 21, 2025, or in the event of an adjournment or postponement of the Meeting, 48 hours before the time of the adjourned or postponed Meeting (excluding Saturdays, Sundays and holidays). Votes cast electronically are in all respects equivalent to, and will be treated in the exact same manner as, votes cast via a paper instrument of proxy. Further details on the electronic voting process are provided in the instrument of proxy.

The Company has elected to use the “notice-and-access” mechanism provided for under National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer to deliver the Meeting materials to non-registered Shareholders, including the Circular, notice of Meeting, consolidated audited financial statements of the Company for the financial years ended December 31, 2024, and 2023 and the auditors’ report thereon and accompanying management’s discussion and analysis. This means that, rather than receiving paper copies of the Meeting materials in the mail, non-registered Shareholders as of the Record Date will have access to electronic copies of the Meeting materials at https://investors.imcannabis.com and under the Company’s SEDAR+ and EDGAR profiles at www.sedarplus.ca and www.sec.gov/edgar. The Meeting materials will remain on the Company’s website for a period of one year. Notice-and-access will not be used for the registered Shareholders and registered Shareholders will instead receive a paper copy of the Meeting materials and all proxy related materials in the mail.

For a description of the matters being considered at the Meeting, please refer to the Circular and Meeting materials.

Additional Information on the Focus Transaction

The Company wishes to provide Shareholders with additional information on the proposed Focus Transaction. To determine the Focus Purchase Price, the Board commissioned an arm’s length independent third-party, Beta Finance T.Y.S Ltd., a leading financial consulting company in Israel. Utilizing a discounted cash flow income approach, they determined the value of Focus, as of December 31, 2024, to be approximately NIS 3.1 million based on the future cash flow expected to be generated by its operations. Applying this analysis, it was determined that a 26% interest in Focus would be worth approximately NIS 818,740.

The Company, IMC Holdings and Ewave agreed that to preserve the Company’s cash, they intend to settle the Focus Purchase Price through the issuance of Common Shares, calculated on the basis of a deemed price per Common Share equal to the greater of: (x) the ten-day volume weighted average price of the Common Shares on the CSE ending on the date the Company receives disinterested shareholders’ approval to complete the Focus Transaction; and (y) the discounted market price pursuant to the policies of the CSE.

The Board (excluding the conflicted director) unanimously determined the Focus Transaction to be in the best interests of the Company and recommends the approval of the Focus Transaction and Focus Transaction Resolution (as such term is defined in the Circular) by disinterested Shareholders at the Meeting.

Your vote is important. Whether or not you plan to attend the Meeting, we encourage you to vote promptly.

About IM Cannabis Corp.

IM Cannabis (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the Company holding the Meeting on the date and time set out herein; the Company’s plan to seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company’s plan to complete the Focus Transaction.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company will hold the Meeting on the date and time set out herein; the Company will seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company completing the Focus Transaction.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s inability to continue to meet the listing requirements of the CSE and the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company’s inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company’s inability to realize upon its retail presence, distribution capabilities and data-driven insights; the Company not holding the Meeting on the date and time as set out herein; the Company not receiving disinterested Shareholder approval to complete the Focus Transaction at the Meeting; the Company not completing the Focus Transaction; and the risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report on Form 20-F dated March 31, 2025, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko,
Director Investor & Public Relations IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/im-cannabis-announces-filing-of-information-circular-for-upcoming-annual-general-and-special-meeting-and-provides-additional-information-on-the-focus-transaction-302448387.html

SOURCE IM Cannabis Corp.

Cision
Cision

View original content: https://www.newswire.ca/en/releases/archive/May2025/07/c2855.html



Source link

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 (updated October 8, 2025) Published by


IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

TORONTO and GLIL YAM, Israel, May 7, 2025 /PRNewswire/ — IM Cannabis Corp. (Nasdaq: IMCC) (CSE: IMCC) (the “Company” or “IM Cannabis“), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the “April 11 Release“), it has filed a management information circular (the “Circular“) in connection with the upcoming annual general and special meeting of the shareholders of the Company (“Shareholders“) to be held on May 23, 2025 (the “Meeting“). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.

 

 

Meeting Details

The Company’s board of directors (the “Board“) has set March 31, 2025 as the record date (the “Record Date“) for determining the Shareholders entitled to receive notice of and vote at the Meeting. The Meeting will be held at the offices of Company’s legal counsel, Garfinkle Biderman LLP, located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9 on Friday, May 23, 2025 at 10:00 a.m. (Toronto time).

To be effective, proxies in respect of the Meeting must be duly completed, signed and returned in the envelope provided for that purpose to Computershare Trust Company of Canada, 8th Floor, 100 University Ave, Toronto, Ontario M5J 2Y1, by courier, by mail, by phone at 1-866-732-8683 (Toll Free North America) / 312-588-4290 (International Direct Dial) or by electronic voting through www.investorvote.com in each case by 10:00 a.m. (Toronto time) on May 21, 2025, or in the event of an adjournment or postponement of the Meeting, 48 hours before the time of the adjourned or postponed Meeting (excluding Saturdays, Sundays and holidays). Votes cast electronically are in all respects equivalent to, and will be treated in the exact same manner as, votes cast via a paper instrument of proxy. Further details on the electronic voting process are provided in the instrument of proxy.

The Company has elected to use the “notice-and-access” mechanism provided for under National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer to deliver the Meeting materials to non-registered Shareholders, including the Circular, notice of Meeting, consolidated audited financial statements of the Company for the financial years ended December 31, 2024, and 2023 and the auditors’ report thereon and accompanying management’s discussion and analysis. This means that, rather than receiving paper copies of the Meeting materials in the mail, non-registered Shareholders as of the Record Date will have access to electronic copies of the Meeting materials at https://investors.imcannabis.com and under the Company’s SEDAR+ and EDGAR profiles at www.sedarplus.ca and www.sec.gov/edgar. The Meeting materials will remain on the Company’s website for a period of one year. Notice-and-access will not be used for the registered Shareholders and registered Shareholders will instead receive a paper copy of the Meeting materials and all proxy related materials in the mail.

For a description of the matters being considered at the Meeting, please refer to the Circular and Meeting materials.

Additional Information on the Focus Transaction

The Company wishes to provide Shareholders with additional information on the proposed Focus Transaction. To determine the Focus Purchase Price, the Board commissioned an arm’s length independent third-party, Beta Finance T.Y.S Ltd., a leading financial consulting company in Israel. Utilizing a discounted cash flow income approach, they determined the value of Focus, as of December 31, 2024, to be approximately NIS 3.1 million based on the future cash flow expected to be generated by its operations. Applying this analysis, it was determined that a 26% interest in Focus would be worth approximately NIS 818,740.

The Company, IMC Holdings and Ewave agreed that to preserve the Company’s cash, they intend to settle the Focus Purchase Price through the issuance of Common Shares, calculated on the basis of a deemed price per Common Share equal to the greater of: (x) the ten-day volume weighted average price of the Common Shares on the CSE ending on the date the Company receives disinterested shareholders’ approval to complete the Focus Transaction; and (y) the discounted market price pursuant to the policies of the CSE.

The Board (excluding the conflicted director) unanimously determined the Focus Transaction to be in the best interests of the Company and recommends the approval of the Focus Transaction and Focus Transaction Resolution (as such term is defined in the Circular) by disinterested Shareholders at the Meeting.

Your vote is important. Whether or not you plan to attend the Meeting, we encourage you to vote promptly.

About IM Cannabis Corp.

IM Cannabis (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the Company holding the Meeting on the date and time set out herein; the Company’s plan to seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company’s plan to complete the Focus Transaction.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company will hold the Meeting on the date and time set out herein; the Company will seek disinterested Shareholder approval to complete the Focus Transaction at the Meeting; and the Company completing the Focus Transaction.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s inability to continue to meet the listing requirements of the CSE and the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company’s inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company’s inability to realize upon its retail presence, distribution capabilities and data-driven insights; the Company not holding the Meeting on the date and time as set out herein; the Company not receiving disinterested Shareholder approval to complete the Focus Transaction at the Meeting; the Company not completing the Focus Transaction; and the risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report on Form 20-F dated March 31, 2025, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko,
Director Investor & Public Relations IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/im-cannabis-announces-filing-of-information-circular-for-upcoming-annual-general-and-special-meeting-and-provides-additional-information-on-the-focus-transaction-302448387.html

SOURCE IM Cannabis Corp.



Source link

Trulieve’s Q1 Was Flat to 2024-Q1 – New Cannabis Ventures

Trulieve’s Q1 Was Flat to 2024-Q1 – New Cannabis Ventures

May 7, 2025 (updated October 8, 2025) Published by


May 7, 2025 at 6:32 am

Published by NCV Newswire

Trulieve Reports First Quarter 2025 Results Demonstrating Core Business Strength
  • First quarter revenue of $298 million, with 62% gross margin
  • Cash flow from operations of $51 million and free cash flow of $34 million*
  • 4/20 holiday season units sold and traffic increased 20% and 9%, respectively, year over year

TALLAHASSEE, Fla., May 7, 2025 /PRNewswire/ — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended March 31, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles unless otherwise indicated. Numbers may not sum perfectly due to rounding.

Q1 2025 Financial and Operational Highlights*

  • Revenue of $298 million increased slightly year over year, with 95% of revenue from retail sales.
  • Achieved gross margin of 62% versus 58% last year, with GAAP gross profit of $183 million.
  • Reported net loss attributable to common shareholders of $33 million. Adjusted net loss of $3 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
  • Achieved adjusted EBITDA of $109 million*, or 37% of revenue, up 3% year over year.
  • Generated cash flow from operations of $51 million and free cash flow of $34 million*.
  • Cash at quarter end was $329 million.
  • Rewards program members reached over 625,000 members as of March 31, 2025. Loyalty members accounted for 68% of transactions during the first quarter.
  • Launched Onward, a premium, non-alcoholic THC beverage available for purchase by consumers 21 years and older at select retail locations in Florida or ordered via DrinkOnward.com for direct shipment to 36 states.
  • Opened six dispensaries in Maricopa, Arizona; Middleburg, North Miami Beach, and Palm Coast, Florida; and Columbus and Zanesville, Ohio. Relocated one dispensary to Lancaster, Pennsylvania.

*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

Recent Developments

  • 4/20 holiday season units sold and traffic increased 20% and 9%, respectively versus last year.
  • Opened one new retail location in St. Petersburg, Florida.
  • Currently operate 229 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.

Management Commentary

“Strong margins and cash flow achieved in the first quarter clearly demonstrate our commitment to operational excellence,” said Kim Rivers, Trulieve CEO. “With our loyal customer base, branded products, and efforts to drive cannabis reform, Trulieve stands out as an industry leader.”

Financial Highlights*

Original press release

Published by NCV Newswire

NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter






Source link

8 things to know about becoming a successful cannabis grower

8 things to know about becoming a successful cannabis grower

May 7, 2025 (updated October 8, 2025) Published by


As the cannabis industry matures across North America, skilled cultivation professionals remain among the most-sought-after talent in the sector.

Behind every successful marijuana retail operation stands knowledgeable growers responsible for producing consistent, high-quality cannabis that meets both regulatory requirements and consumer expectations.

If you’re looking to enter this specialized field, understanding the multifaceted nature of commercial cannabis cultivation is essential.

Here are eight critical areas of knowledge and expertise required to succeed as a professional cannabis grower in today’s competitive environment:

1. Understand state rules, compliance requirements

Cannabis cultivation remains one of the most heavily regulated agricultural activities in North America.

Each state maintains distinct regulatory frameworks governing everything from facility security requirements to pesticide restrictions and product-testing protocols.

Successful dispensary growers must:

  • Obtain proper licensing and credentials specific to your jurisdiction.
  • Maintain detailed documentation of cultivation processes, inventory and environmental conditions.
  • Implement track-and-trace compliance systems for seed-to-sale monitoring.
  • Stay current with evolving regulations that frequently change as markets mature.

Marijuana retailers value growers who not only produce exceptional cannabis but also understand regulatory constraints and documentation requirements.

Demonstrating knowledge of compliance procedures can significantly enhance your employability in this regulated market.

2. Master controlled environment agriculture principles

Commercial cannabis cultivation has evolved far beyond traditional growing methods.

Today’s cultivation operations typically utilize sophisticated controlled environment agriculture (CSE) approaches that require specialized knowledge:

  • Climate control systems maintaining precise temperature and humidity parameters.
  • Advanced lighting technologies, including LED spectrum manipulation.
  • Automated irrigation and fertigation delivery systems.
  • Environmental monitoring equipment tracking dozens of variables.
  • CO2 supplementation systems for enhanced photosynthesis

Successful growers combine traditional plant knowledge with technical expertise in managing these complex cultivation environments.

Formal education in horticulture, plant science or CSE provides a valuable foundation, with cannabis-specific training building upon these fundamentals.

3. Develop extensive plant-health management skills

Preventing and addressing plant-health issues represents one of the most critical responsibilities in commercial cultivation.

With crop values often exceeding thousands of dollars per square foot, cannabis growers must develop comprehensive integrated pest management (IPM) approaches:

  • Preventative biological controls, including beneficial insects and microorganisms.
  • Early identification of nutrient deficiencies and toxicities.
  • Strategic application of approved organic and conventional treatments.
  • Diagnosis and remediation of complex plant-health issues.

The ability to maintain plant health while adhering to strict testing requirements for contaminants represents a premier skill set in the industry.

Growers with demonstrated success managing plant health within organic or restricted-input protocols are particularly valued.

4. Build a foundation in cannabis genetics, breeding

Product differentiation increasingly drives retail success, with genetics serving as the foundation for unique product offerings.

To achieve that, professional growers should develop knowledge in:

  • Phenotype selection and stabilization techniques.
  • Maintenance of mother plants and cloning protocols.
  • Breeding approaches for developing proprietary cultivars.
  • Genetic preservation methods including tissue culture.
  • Terpene and cannabinoid expression in different genetic lines.

Understanding the relationship between genetics, cultivation techniques and final product attributes allows growers to consistently produce cannabis that meets specific market demands, whether focused on particular cannabinoid profiles, unique terpene combinations or visual characteristics valued by consumers.

5. Master post-harvest processing and quality control

The cultivation process extends well beyond the growth cycle, with harvesting, drying, curing and processing representing critical phases determining final product quality.

Professional growers should develop expertise in:

  • Harvest timing optimization for desired cannabinoid and terpene profiles.
  • Environmental control during drying and curing phases.
  • Quality-assessment protocols for moisture content, terpene preservation and cannabinoid stability.
  • Handling techniques minimizing trichome damage and product degradation.
  • Batch documentation and testing coordination.

These post-harvest skills directly impact product shelf life, consumer experience and, ultimately, retailer profitability.

Growers who understand the science behind these processes can consistently deliver premium products commanding higher market values.

6. Develop business acumen, cost-management skills

Professional cultivation requires balancing biological ideals with economic realities.

In high demand are growers who understand the business dimensions of their role, including:

  • Resource optimization strategies reducing production costs.
  • Energy efficiency approaches minimizing electricity consumption.
  • Labor-management techniques improving operational efficiency.
  • Yield forecasting and production scheduling.
  • Cost-benefit analysis for cultivation investments.

The ability to communicate how cultivation decisions impact business metrics strengthens a grower’s position as a strategic team member rather than simply a technical specialist.

This marijuana business perspective proves particularly valuable when a grower advances into management roles within cultivation operations.

7. Lean on a professional network, boost expertise

The cannabis cultivation field is evolving rapidly, with new technologies, methodologies and research continually emerging.

To keep up with this evolution, successful growers:

  • Maintain active membership in professional organizations.
  • Attend industry conferences and technical workshops.
  • Participate in cultivation-focused online communities.
  • Build relationships with agricultural suppliers and technology providers.
  • Stay current with scientific literature and research developments.

These connections provide not only valuable knowledge but also career-advancement opportunities.

Growers frequently are recruited through professional networks rather than traditional job postings, particularly for senior cultivation positions.

8. Develop specialized knowledge in emerging areas

The cannabis industry increasingly values specialized expertise beyond general cultivation knowledge.

Developing deep knowledge in emerging areas can significantly enhance your professional value:

  • Living soil and organic cultivation methodologies.
  • Water remediation and conservation systems.
  • Advanced plant-training techniques maximizing canopy efficiency.
  • Specialized lighting strategies optimizing photomorphogenesis.
  • Cultivation approaches for specific extract and concentrate production.

This specialized knowledge becomes particularly valuable as markets mature and consumers develop more sophisticated preferences requiring tailored cultivation approaches.

Subscribe to the MJBiz Factbook  

Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype. 

What you will get: 

  • Monthly and quarterly updates, with new data & insights
  • Financial forecasts + capital investment trends
  • State-by-state guide to regulations, taxes & market opportunities
  • Annual survey of cannabis businesses
  • Consumer insights
  • And more!

Importance of putting together all eight categories

Becoming a successful marijuana grower requires a multidisciplinary skill set combining traditional agricultural knowledge, technical expertise, regulatory understanding and business acumen.

By developing comprehensive capabilities across these eight areas, aspiring cultivation professionals can position themselves as valuable assets in the competitive marijuana industry landscape.

As the marijuana industry continues maturing, those combining hands-on experience with formal education and specialized knowledge will find themselves increasingly sought after by quality-focused operations committed to cannabis cultivation excellence.

(Note: AI assisted in summarizing the key points for this story.)



Source link

DOGE touts cut to federally funded cannabis research (Newsletter: May 7, 2025)

DOGE touts cut to federally funded cannabis research (Newsletter: May 7, 2025)

May 7, 2025 (updated October 8, 2025) Published by


PA House passes legal cannabis bill on initial vote; VA’s marijuana proposal; FBI approves DE cannabis background check plan; CO psychedelics

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen.

If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment

/ TOP THINGS TO KNOW

The Pennsylvania House of Representatives passed a bill to legalize marijuana sales through a system of state-owned stores on second reading. A separate vote on third reading, expected soon, would formally send the measure to the Senate.

The Department of Government Efficiency (DOGE) is touting the cancellation of a federal contract for “potency monitoring of confiscated marijuana samples” worth $142,839 that the National Institute on Drug Abuse awarded to the University of Mississippi.

The Department of Veterans Affairs is seeking price quotes from contractors who can help analyze and explain scientific evidence on medical marijuana to clinicians and the public—including potential benefits for conditions like PTSD as well as potential risks around cannabis use disorder.

The Federal Bureau of Investigation partially approved background check language in Delaware’s revised marijuana law, allowing the state’s recreational cannabis market to proceed toward launching—though lawmakers still need to fix one overly broad definition for full approval.

Colorado lawmakers sent Gov. Jared Polis (D) a bill to empower the governor to grant pardons to people who’ve been convicted of psychedelics-related offenses, and to revise rules for legal psychedelic products and healing centers.

Nevada lawmakers are considering a bill to stop automatically disqualifying people from becoming foster parents due to past marijuana convictions.

/ FEDERAL

Rep. Ilhan Omar (D-MN) tweeted, “As Co-Chairs of the Congressional Cannabis Caucus, @repdinatitus and I joined cannabis advocates in pushing for equity-focused cannabis laws that ensure folks across the country are given the second chance they deserve.”

The House bill to create psychedelics-focused innovative therapies centers of excellence got one new cosponsor for a total of seven.

/ STATES

Maryland Gov. Wes Moore (D) signed legislation to add members to the Cannabis Public Health Advisory Council.

The Minnesota House of Representatives passed an omnibus cannabis policy bill.

The California Assembly Revenue & Taxation Committee approved a bill to halt a planned cannabis tax increase.

The Maine legislature’s Veterans and Legal Affairs Committee held a hearing on nine bills to change various cannabis rules.

An Illinois representative spoke at a press conference about the need to reduce licensing fees and regulations faced by social equity marijuana businesses.

The nominee to be Delaware’s top marijuana regulator will have a confirmation hearing on Wednesday.

Michigan regulators banned a man from participating in the legal marijuana industry after he allegedly sold cannabis to an underage undercover police cadet.

Rhode Island regulators are conducting a survey of people who are interested in applying for a retail marijuana business license.

New York regulators are accepting proposals to speak at a medical cannabis symposium on November 7.

The Virginia Cannabis Control Authority Board of Directors will meet on Wednesday.

Georgia regulators will consider medical cannabis production license contracts on Wednesday.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

/ LOCAL

Mendocino County, California and its sheriff are being sued by the Round Valley Indian Tribes over allegedly illegal raids on cannabis farms.

/ INTERNATIONAL

The German Federal Court of Justice overturned a lower court’s interpretation of what quantities of cannabis are considered serious enough to warrant searches of suspects’ online data.

/ SCIENCE & HEALTH

A review concluded that “CBD offers a promising therapeutic approach for breast cancer, especially for aggressive subtypes.”

A study found “evidence of a weak positive correlation between distance from cannabis dispensaries and favorable attitudes toward [medicinal cannabis], with gender and state legal status contributing to attitudes, while dispensary density did not significantly impact attitudes.”

/ ADVOCACY, OPINION & ANALYSIS

The Heroic Hearts Project and Healing Breakthrough are merging.

Strategies 64 published a white paper on cannabis labeling issues.

/ BUSINESS

TerrAscend Corp. is acquiring Union Chill Cannabis Company LLC.

/ CULTURE

Tucker Carlson said the first time you smoke marijuana is “truly fun” but “that doesn’t ever happen again.”

Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link